Navigation Links
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
Date:7/30/2009

ions to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to the effective date of transfer of Sunesis' common stock to The NASDAQ The Capital Market and Sunesis compliance with The NASDAQ Capital Markets' continued listing requirements. Words such as "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis fails to comply with the continued listing requirements of The NASDAQ Capital Market and that Sunesis may be subject to delisting proceedings in the future. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Investor Contact:                          Media Contact:
    Sunesis Pharmaceuticals, Inc.              Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt   
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... ICLL) today announced that the Australian Therapeutic Goods,Administration ... to,prevent Japanese Encephalitis. This final decision step for ... Australian Drug Evaluation,Committee (ADEC) in December 2008. , ... Australian authorities represents the first,regulatory approval for the ...
... Aerolase Corporation, a leading manufacturer of next-generation portable ... sales increased dramatically in 2008 over 2007. The ... market helped to more than offset current economic ... record sales month for Aerolase, and 2008 overall ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
Cached Biology Technology:Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2
(Date:10/22/2014)... JOSE, Calif. , Oct. 20, 2014 ... the United States Air Force Research Laboratory (AFRL), has ... Integrative Medicine (AzCIM) at the University of Arizona College ... receive research funding.  The AzCIM project,s goal is to ... ability to collect different volumes of sweat under a ...
(Date:10/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its third quarter ended September 30, 2014. Revenue ... increase of 40% compared to $4.3 million in the same ... 2014 was $4.1 million compared to $1.0 million in the ... three month period was primarily due to: i) a $1.0 ...
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... drop in public concern over global warming, Americansregardless of political ... to the results of a national survey released today by ... survey found support for: , Funding more research ... percent) Tax rebates for people buying fuel-efficient vehicles ...
... , BLUE BELL, Pa. , Feb. ... announced that its Mexican subsidiary has been awarded a contract ... of Internal Affairs/National Citizen Registry) to create and manage an ... create a database with iris, fingerprint and facial biometric data ...
... available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-02/sfeb-cbc020310.php,">Chinese . ... do Paran and Instituto Carlos Chagas have ... expanded CD133+ cells human umbilical cord blood ... injecting them into a rat model. Patients ...
Cached Biology News:According to new survey, Americans support strong climate, energy policies 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 3
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
... These 1.5L PYREX trypsinizing flasks ... tissue samples into cell suspensions ... Heavy beaded neck accepts cotton ... vigorous agitation. • Height of ...
... Application: For the efficient enrichment ... mammalian tissue or cell culture. The ... synthesis, degradation and metabolic pathway analysis. ... acetyltransferase deficiency in children, cystic fibrosis ...
Biology Products: